Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IAC Regimen in Relapsed/Refractory AML
NCT02937662Phase 2Completed
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Oct 2016
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cyclophosphamide in acute myeloid leukemia (AML), sponsored by Institute of Hematology and Blood Diseases Hospital. Started Oct 2016; status: completed.
02
Drugs
cyclophosphamide
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02937662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02937662.